Tab%252525252525252525252525252525252525252525252525252525252520linagliptin

# Linagliptin ## Overview Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone activity, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primarily biliary excretion, allowing for clinical use without dose adjustments in renal impairment. ## Primary Indications Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ## Adult Dosing * **Standard Dose:** 5 mg orally once daily. * **Maximum Dose:** 5 mg daily. ## Pediatric Dosing * **Safety and Efficacy:** Not established in pediatric patients (<18 years). Use is not recommended. ## Dose Adjustments * **Renal Impairment:** No dose adjustment necessary regardless of stage (including ESRD). * **Hepatic Impairment:** No dose adjustment necessary. ## Contraindications * History of a serious hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions). ## Adverse Effects * **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or secretagogues). * **Serious:** Acute pancreatitis (discontinue if suspected), bullous pemphigoid, severe arthralgia, hypersensitivity reactions. ## Key Drug Interactions * **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin efficacy. If possible, avoid concomitant use. * **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; consider down-titration of the concomitant insulin or secretagogue when initiating linagliptin. ## Monitoring * **Glycemic Control:** HbA1c (typically every 3–6 months), fasting plasma glucose. * **Pancreatitis:** Monitor for signs of severe, persistent abdominal pain. * **Skin:** Monitor for blistering/erosive lesions suggestive of bullous pemphigoid. ## Clinical Pearls * **Renal Advantage:** Often preferred in patients with chronic kidney disease because it does not require dosage titration for creatinine clearance. * **Administration:** Can be taken with or without food. * **Weight Influence:** Linagliptin is considered weight-neutral. * **Mechanism:** Does not cause hypoglycemia as monotherapy; hypoglycemia risk arises only with combination therapy involving insulin or sulfonylureas. *** *Disclaimer: This information is for educational purposes only. Clinical guidelines and prescribing information change frequently. Always consult the most recent FDA-approved prescribing information or institutional protocols before prescribing or administering medication.*